Chemistry Reference
In-Depth Information
[15] Melo EB, Gomes, AS, Carvalho I. α- and β-Glucosidase inhibitors: chemical structure and biological activity.
Tetrahedron 2006; 7; 62: 10277-10302.
[16] Balzarini J. Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy. Nat. Rev.
Microbiol 2007; 5: 583-597.
[17] Nasi R, Patrick BO, Sim L, Rose DR, Pinto BM. Studies Directed toward the Stereochemical structure
determination of the naturally occurring glucosidase inhibitor, kotalanol: synthesis and inhibitory activities
against human maltase glucoamylase of seven-Carbon, Chain-Extended Homologues of salacinol. J Org Chem
2008; 24; 73(16): 6172-6181.
[18] Silva CHTP, Carvalho I, Taft CA. Homology modeling and molecular interaction field studies of α-
glucosidases as a guide to structure-based design of novel proposed anti-HIV inhibitors. J. Comput.-Aided
Mol. Des. 2005; 19: 83-92.
[19] Gomes AS, Silva CHTP, Silva VB, Carvalho I. Structure and ligand-based drug design to propose novel α-
glucosidase inhibitors. Current Biactive Compounds 2009; 5: 99-109.
[20] Zhang J, Wang Q, Fang H
et al.
Design, synthesis, inhibitory activity and SAR studies of pyrrolidine
derivatives as neuraminidase inhibitors. Bioorg. Med. Chem
2007; 1; 15(7): 2749. 2749-2758.
[21] Itzstein MV. Disease-associated carbohydrate-recognising proteins and structure-based inhibitor design. Curr.
Opin. Struct. Biol., 2008; 18: 558-566.
[22] Itzstein MV. The war against influenza: discovery and development of sialidase inhibitors. Nat. Rev. Drug
Discov. 2007; 6(12), 967-974.
[23] Fátima A, Baptistella LHB, Pilli RA. Ácidos siálicos-da compreensão do seu envolvimento em processos
biológicos ao desenvolvimento de fármacos contra o agente etiológico da gripe. Quim. Nova
2005; 11; 28(2):
306-316.
[24] Colman PM. Influenza virus neuraminidase: structure, antibodies, and inhibitors
Protein Sci. 1994; 3: 1687-
1696.
[25] Itzstein MV, Dyason JC, Oliver SW
et al.
A study of the active site of influenza virus sialidase: an approach to
the rational design of novel anti-influenza drugs.
J. Med. Chem.
1996; 39: 388-391.
[26] Hanessian S, Wang J, Montgomery D
et al.
Design, synthesis, and neuraminidase inhibitory activity of GS-
4071 analogues that utilize a novel hydrophobic paradigm. Bioorg. Med. Chem. Lett.
2002; 2; 12(23): 3425-
3429.
[27] Kim CU, Lew W, Willians MA
et al.
Influenza neuraminidase inhibitors possessing a novel hydrophobic
interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid
analogues with potent anti-influenza activity. J. Am. Chem. Soc.
1997; 119: 681-690.
[28] Itzstein MV. Avian influenza vírus, a very sticky situation. Curr. Opin. Chem. Biol. 2008; 12: 102-108.
[29] Linares GEG, Ravaschino EL, Rodriguez JB. Progresses in the field of drug design to combat tropical
protozoan parasitic diseases
.
Curr Med. Chem. 2006; 13(3): 335-360.
[30] Renslo R, Mckerrow JH. Drug discovery and development for neglected parasitic diseases. Nature Chem. Biol
2006; 2: 701-710.
[31] Gascón J, Albajar P, Canãs E
et al.
Diagnosis, management, and treatment of chronic chagas´heart is not
endemic.Rev. Esp Cardiol. 2007; 60: 285-293.
[32] Word Health Organization. Reporte del grupo de trabajo científico sobre la enfermedad de Chagas
.
2005.
Buenos Aires. WHO, 2007.
[33] Previato LM, Previato JO, Jones C
et al.
Structure of
O
-glycosidically linked oligosaccharides from
glycoproteins of
Trypanosoma cruzi
CL-Brener strain: evidence for the presence of
O
-linked sialyl-
oligosaccharides. J. Biol. Chem. 1995; 270: 7241.
[34] Ribeirão M, Pereira-Chioccola VL, Eichinger D
et al.
Temperature differences for
trans
-glycosylation and
hydrolysis reaction reveal an acceptor binding site in the catalytic mechanism of
Trypanosoma cruzi
trans
-
sialidase. Glycobiology 1997; 7: 1237.
[35] Buschiazzo A, Amaya MF, Cremona ML
et al.
The crystal structure and mode of action of
trans
-sialidase, a
key enzyme in
Trypanosoma cruzi
pathogenesis.
Molecular Cell 2002; 10(4): 757-768.
[36] Agrellos OA, Jones C, Todeschini AR
et al.
A novel sialylated and galactofuranose-containing
O
-linked
glycan, Neu5Acα2→3Galpβ1→6(Galfβ1→4)GlcNAc, is expressed on the sialoglycoprotein of
Trypanosoma
cruzi
Dm28c.
Mol. Biochem. Parasit. 2003; 126: 93-96.
[37] Buscaglia CA, Campo VA, Frasch ACC
et al. Trypanosoma cruzi
surface mucins: host-dependent coat
diversity. Nat Rev Microbiol 2006; 4(3): 229-236.
